Guardant Health, a precision oncology company, has purchased the remaining shares of Guardant Health AMEA from SoftBank, giving the company control over its operations.

The deal allows GH to address the cancer burden in the region by accelerating the adoption of the company’s blood tests.

“By acquiring the remaining shares of Guardant Health AMEA, we can focus on creating a unified and centralized global organization that delivers on our promise to help conquer cancer,” said Helmy Eltoukhy, Guardant Health co-CEO. “We believe our blood-based tests can play a significant role in helping address the growing incidence of cancer in the region, and we look forward to continuing to support patients facing cancer diagnoses as we expand our operations in these markets.”